GLP2-TZ
A dual GIP/GLP-1 receptor agonist. Research explores incretin signaling, glycemic control, gastric emptying, and body composition changes in metabolic disease models.
Unit Price
Sign in to view pricing.
Purchase requires a verified researcher account and a signed RUO attestation.
All batch test results and certificates of analysis are published below — including any batches that failed testing. Full transparency is our standard.
Mechanism of Action
Tirzepatide is a 39-amino-acid dual GIP/GLP-1 receptor agonist engineered from the GIP sequence with GLP-1 activity. GLP-1 activation enhances glucose-dependent insulin release, slows gastric emptying, and promotes satiety. GIP co-agonism amplifies insulin secretion and modulates adipose tissue function. SURPASS trials demonstrated HbA1c reductions of 1.24-2.58% and weight reductions of 5.4-11.7 kg at weekly doses of 5-15 mg.
Research References
Full research page →Min T, Bain SC. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials. Diabetes Ther. 2021. PMID: 33325008
Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes. Cardiovasc Diabetol. 2022. PMID: 36050763
Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022
Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021
Batch History & Certificates of Analysis
Full Batch Record
Active Batches
TR10-2026-001
Received Apr 15, 2026
Qty Received
10 units
No test results on record for this batch.
For Research Use Only. This product is supplied exclusively for in vitro research, laboratory study, and experimental purposes. It is not a drug, supplement, food, or cosmetic, and is not intended for human or veterinary use. See our Compliance & RUO Policy.